COVAXIN, India’s first indigenous COVID-19 vaccine after receiving emergency use authorization (EUA) from WHO (World Health Organization) has been added to the USA’s list of approved jabs for international travelers from November 8, with the UK following suit, rather instantly.
USA’s Centers for Disease Control (CDC) has granted approval to FDA-approved or authorized, and WHO Emergency Use Listing vaccines. With Oxford-AstraZeneca-developed Covishield already on the list, COVAXIN is the second entrant which will allow Indian travelers to enter the US soil without any fuss.
After months of dillydallying by the WHO in granting the approval, the floodgates have finally opened and COVAXIN is well on its way to providing the entire globe and its population a safe, reliable and affordable vaccine.
Americans finally have an alternative, can ditch mRNA vaccines:
An article on American Bazaar written by Craig Snyder, says that COVAXIN is the best vaccine out there but is unfortunately not available to Americans. Many people in the USA are refusing to take the mRNA vaccines, but they don’t agree with being called ‘anti-vaxxers’.
They just want a choice beyond mRNA vaccines, a choice that COVAXIN provides. Unfortunately, it is only the mRNA vaccines of Pfizer and Moderna that have been so far shoved down the throats of common Americans. The Bharat Biotech developed vaccine can help countries like USA win over their anti-vax populace.
COVAXIN developed using old, reliable methods:
COVAXIN has been manufactured using a live virus, that is, using a manufacturing process that has been used in childhood vaccines for polio and other diseases, for decades. Succinctly put, COVAXIN is the best vaccine out there to address the hesitancy of millions of Americans with respect to the mRNA vaccines.
Moreover, the two mRNA vaccines are incredibly expensive, which the poor, underdeveloped Americans cannot afford. COVAXIN is relatively cheaper and does not need the extreme logistical apparatus like the mRNA vaccines, to be administered.
Cheaper and easier to store:
Moderna costs around $32 to $37 and Bharat Biotech’s COVAXIN costs merely $3 to $5. When we talk about compatibility, COVAXIN is more storage-friendly than other vaccines.
For instance, Pfizer needs to be kept in extremely cold temperatures of minus 70 degrees Celsius, the cost of which may go into billions, whereas COVAXIN requires only 2-8 degrees Celsius cold chain, which is much more viable for warm, developing and underdeveloped nations.
Moreover, the efficacy of COVAXIN is unrivaled. Compared to other publicly available data, it shows the best neutralization titers against variants of concern – Delta and Beta, and even out performs on those measures compared with people previously infected with the original COVID-19 strain.
Shadowy performance of Sinopharm, Pfizer, and other mRNA based vaccines:
According to reports, in Malayasia, Out of 2159 deaths of people who were fully vaccinated, 1573 or 72.8 percent were inoculated with the Chinese Sinovac. 550 or 25.5 percent were jabbed with the Pfizer vaccine.
Malaysia: Out of 2159 deaths of people who were fully vaccinated, 1573 or 72.8% were inoculated with the Chinese Sinovac. WHO took just days to give EUL to Sinovac, months for Covaxin. pic.twitter.com/gJEhCxOakf
— Shubhangi Sharma (@ItsShubhangi) November 8, 2021
The world is desperate to break the duopoly of Pfizer and Moderna. Reportedly, the Covid-19 death toll in the USA this year has already surpassed the number of fatalities in 2020. The wave fuelled by the Delta variant is waning in the USA, but daily infections are still hovering near 75,000 on average. The USA has only administered mRNA vaccines to its populace.
As reported by TFI back in March, Israel thought it had flattened the Covid-19 curve, as more than half of the country’s 9.3 million population had received two jabs of Pfizer vaccine. However, things went quickly downhill thereafter as another bout of massive infection numbers started to spurt. As a result, countries had started tagging Israel as a high-risk destination for travellers.
Will not be a smooth sailing for COVAXIN:
It’s not to say, it will be smooth sailing for COVAXIN in the states. The Pfizer-Moderna lobby has pumped far too much money in its marketing campaign to back down now. If the example of Brazil is anything to go by – Bharat Biotech will need to stay put and play fire with fire.
Reportedly, the Brazilian government had first tied up with the Hyderabad-based company for the commercialization of COVAXIN in the country. However, soon, US-based actors masquerading as NGO activists leveled allegations of corruption in the deal. Jair Bolsonaro initially shrugged off the challenges but eventually succumbed to the incessant hounding campaign by the lobby.
– Namaskar, Primeiro Ministro @narendramodi
– O Brasil sente-se honrado em ter um grande parceiro para superar um obstáculo global. Obrigado por nos auxiliar com as exportações de vacinas da Índia para o Brasil.
– Dhanyavaad! धनयवाद pic.twitter.com/OalUTnB5p8
— Jair M. Bolsonaro (@jairbolsonaro) January 22, 2021
The Brazilian government suspended the contract based on the cacophony of a few activists and seeing the outrage, Bharat Biotech cut its losses and backed out of the South American country in July, earlier this year.
India fought off the WHO hurdle and emerged victoriously:
It has been the modus operandi of Big Pharma companies of the USA to force their way through in the markets and sell their medicines at inflated prices. It tried the same in India, but the Modi government with its guard up, fended off the attacks.
COVAXIN entering the USA didn’t come easy. WHO, which approved the Sinopharm vaccine in under record 10 days for EUA, continued to delay COVAXIN’s authorization. However, when Indian subtly flexed its muscles by delaying the supply to the Covax program, WHO was forced to take notice and instantly clear the bureaucratic hurdles in the approval of COVAXIN.